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This publication is the result of an exemplary collabo-
ration between the World Health Organisation
(WHO), the United Nations International Drug
Control Programme (UNDCP) and the European
Monitoring Centre for Drugs and Drug Abuse (EMCD-
DA). Already in 1996 UNDCP and WHO initiated joint
work towards the development of tools for pro-
gramme managers to carry out evaluation of their
existing treatment approaches and to help them
decide on the allocation of resources and access to
effective treatment to their patients. A series of work-
books on evaluation of treatment were prepared and
field tested in several countries, and should be seen as
complimentary to the present guidelines, for training
and planning purposes. 
The association of the EMCDDA with this project
started in 1997 in Athens with a seminar organised
jointly by the EMCDDA, the Greek National Focal
Point and WHO. The seminar aimed at reaching con-
sensus among key European scientists, networks and
policy makers in the area of drug abuse treatment
evaluation and the role of the EMCDDA in this field.
Since then, the EMCDDA became a partner of WHO
and UNDCP in this project, and will now contribute to
the diffusion of the guidelines and the associated
workbooks across the EU.
Since the inception of the project, further international
developments have occurred and need mention. The
Declaration on the Guiding Principles of Drug Demand
Reduction and the Action Plan for its implementation
adopted by United Nations Member States in 1998
and 1999 respectively, highlight the importance and
need for evidence-based practices as well as of learn-
ing from experiences. These are key pillars for the
development and implementation of enhanced drug
demand reduction strategies and programmes, a tar-
get to be reached by Member States by 2003 in
accordance with the 1998 UN General Assembly
Political Declaration on the Drug Problem. The
UNDCP is committed to providing guidance and assis-
tance to Member States in reaching this target, and
views these guidelines for treatment evaluation and
the workbook series as key instruments to encourage
the assessment of the effectiveness of drug abuse
treatment strategies and activities, and the exchange
of evaluation results.
The Helsinki European Summit endorsed the EU Drug
Strategy 2000-2004 in December 1999. The Strategy
provides a framework for all drug-related activities in
the EU over the next five years. The European Union
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Action Plan on Drugs (2000-2004) set out an agreed
programme for the implementation of the principles
and targets set in the Strategy. The Action Plan states
that The European Monitoring Centre on Drugs and
Drug Addiction will establish guidelines for the evalua-
tion of drug policies in Europe.
The World Health Organisation decided to make 2001
the year for Mental Health. One of the major objec-
tives of the coming World Health Assembly 2001,
World Health Day 2001, and the World Health Report
in 2001 will be the control of mental health problems.
The promotion of this objective through the WHO will
also include recommendations for effective service
delivery in the field of substance dependence. The
present guidelines will serve as one step towards
improved treatment for psychoactive substance disor-
ders internationally.
In the past, evaluation of treatment services has not
been recognised as a means to enhance the efficacy of
existing services. However, due to recent developments
in health and social care systems, and budget con-
straints, the need for more systematic evaluations has
increased. Evaluations not only help to justify financial
support for treatment services; they are also essential
to increase and maintain best clinical practice. The suc-
cess of future evaluations will partly depend on the
availability of information on how to implement and
plan evaluations. For this reason, practical and compre-
hensive guidance on evaluation is necessary. This publi-
cation is especially addressed to policy makers, pro-
gramme managers and service providers in the field of
drug demand reduction who will find the guidelines a
unique source of reference. The guidelines will help
decisions to be made about critical aspects, especially
at the moment of conceptualising, planning and com-
missioning the evaluation of treatment services. They
should also serve as a valuable reference in designing
evaluation and to make optimal use of available
resources. In order to improve drug demand reduction
policies in the area of assistance to drug abusers, the
guidelines are also aimed at disseminating critical, sci-
entifically supported knowledge in this regard. 
We would like to thank the authors of the guidelines
for providing a compact and succinct overview of dif-
ferent types of evaluation. We would also like to
express our thanks to all experts and policy makers
who helped to review the guidelines by providing their
valuable comments on earlier drafts.
WHO/UNDCP/EMCDDA
Foreword to the WHO/UNDCP/EMCDDA
guidelines for treatment evaluation 
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6We have tried to prepare the guidelines using a
non-technical language. Nevertheless, some evalua-
tion issues of a more technical nature have been
covered in Section 3: Special Issues. Those who wish
to read a more general account of evaluation meth-
ods and issues should skip this section. Finally, we
do encourage those planning an evaluation to
obtain expert advice wherever feasible. Getting
appropriate advice early on in the planning of an
evaluation is very important and can ensure that
appropriate resources are identified, that the correct
evaluation design is selected, and the data is analy-
ses and correctly presented.
We hope to find the guidelines useful and warmly
welcome feedback and suggestions. 
Please write to:
World Health Organization (WHO)
Management of Substance Dependence
Department of Mental Health 
and Substance Dependence
Avenue Appia 20
1211 Geneva 27
Switzerland
These guidelines describe methods for the evalua-
tion of treatment services and systems for substance
use disorders. The guides are intended to be a com-
panion resource to the World Health Organization
(WHO), United Nations Drug Control Program
(UNDCP) and European Monitoring Centre on
Drugs and Drug Addiction (EMCDDA) workbook
series on the evaluation of costs and effects of treat-
ment for substance use disorders, co-ordinated by
Dr. Maristela Monteiro and Dr Brian Rush (WHO,
2000). 
The main audience is policy makers, commissioners
of treatment services and treatment agency person-
nel who want to know more about research evalua-
tion and commission or undertake evaluation stud-
ies. We hope that there will be much to interest the
international research community as well. 
The guidelines are intended to be of particular inter-
est for countries where research and evaluation in
this area is not widely developed. Our aim is to offer
a concise description of the main evaluation meth-
ods and to help the reader to select the best type of
study to answer specific questions. The goal is to
encourage readers to the use of evaluation to help
develop and maintain effective and efficient treat-
ment services and treatment systems.
These guidelines are not intended to be a detailed,
step-by-step instruction manual on how to do
research. The interested reader should obtain the
related series of workbooks which cover this in
detail (WHO/UNDCP/EMCDDA, 2000). We have
referred to particular workbooks in several places for
further reading and this document is a natural com-
panion to the series. There are also other valuable
sources of information which can be accessed via
the internet. For example, valuable information can
be found at the Cochrane Collaboration site for
information on treatment effectiveness (see
http://www.cochrane.org); an evaluation instrument
bank can be accessed at the ECMDDA site (see
http://www.emcdda.org); and a series of best prac-
tice guides on treatment and evaluation issues can
be obtained from the US Center for Substance
Abuse Treatment (see http://text.nlm.nih.gov). 
Preface
7The misuse of illicit drugs, prescription drugs or alco-
hol is a world-wide problem and there is an interna-
tional commitment to providing prevention and
treatment services. Estimates have suggested that
the annual global population prevalence of illicit
drug use is between three and four percent; preva-
lence estimates for heroin and cocaine use are
approximately 8 million and 13.3 million adults
respectively (United Nations International Drug
Control Programme [UNDCP], 1997). Prescription
drug abuse is known to be high in some countries
(Adams et al., 1993) and alcohol-related problems
can far exceed those involving all other drugs in
term of prevalence and costs to society (Single et al,
1996). Several different types of services and treat-
ments have been developed for substance abuse dis-
orders. These can be broadly categorised as follows:
n “Open access” services:
n advice, education, information, early interven-
tion programmes;
n needle/syringe exchange programmes (in some
nations/regions)
n “Structured” services: 
n prescribing interventions (inpatient and outpa-
tient/community settings);
n community-based psychosocial counselling and
relapse prevention;
n residential rehabilitation programmes
These five categories are really only part of the pic-
ture. Social reintegration and support services may
sometimes be available to support treatment gains
from the above services. Space does not permit us
to give a full account of the various modalities of
treatment and the array of different providers. These
concern the specific approach or philosophy of a
treatment – such as maintenance or reduction
regimes in substitution treatment for opiate users, or
the style of psychosocial counselling (e.g. cognitive
behavioural), or the philosophy of residential reha-
bilitation (e.g. 12-step; therapeutic community). 
It is quite common for a treatment programme to
contain several different therapeutic components
linked together (e.g. methadone maintenance with
cognitive behavioural psychotherapy). It is also quite
common for a person with substance-related diffi-
culties to receive health and social care services from
several service providers during the course of their
treatment. Support and assistance may also come
from the family and friends and other support net-
works. These practical aspects of treatment have
implications for how evaluation research in this field
is constructed and the questions addressed.
There is reason for optimism about investing in the
treatment of people with substance-related prob-
lems. Many careful studies have shown that treat-
ment can result in short, medium, and sometimes
long-term reductions in substance use, improve-
ments in health and reduced demands placed on
health and social services among those treated (see
reviews by Landry 1995; Miller and Hester, 1986;
WHO Expert Committee on Drug Abuse, 1996;
Roberts and Ogborne, 1999; National Institute on
Drug Abuse, 1999). There is also good evidence
that some types of treatment can reduce criminality
and the associated costs of law enforcement among
substance abusers who maintain their habits by
crime (Tims, 1995). The economic benefits of treat-
ment can also exceed treatment costs (Holder and
Blose, 1992; Holder et al., 1991; Centre for
Substance Abuse Treatment, 1999) and by the same
criteria, treatment compares favourably with inter-
diction and other law enforcement efforts directed
at individual drug users (Rydell and Everingham,
1994).
Structure of the Guidelines
The guidelines have four sections. Section 1 sets the
stage for evaluation research and describes the
importance of assessing the feasibility of a study in
terms of the questions to be addressed, the
resources required, ethical considerations and consul-
tation with interested parties. Section 2 summarises
the key features of the five main types of research
evaluation: needs assessment, process evaluation,
client satisfaction studies, outcome evaluation and
economic evaluations. Section 3 describes seven spe-
cial issues of a more technical nature: the reliability,
validity and sensitivity of measures, reliability of self-
report data, time periods for measures, assessing
non-treatment factors that may affect outcome, sub-
ject recruitment and follow-up, sampling and sample
size, and statistical analysis and testing. Section 4
offers guidance of report writing and ensuring results
from evaluation studies are effectively presented to
key audiences. 
Background
An evaluation is done when one wants to assess the
costs, effects or impact of a treatment or treatment
system. Evaluation therefore provides feedback to
key audiences to help them with various types of
decisions. A healthy culture for evaluation is one
that encourages the routine collection and dissemi-
nation of information to help improve how services
are delivered. Nevertheless, in many countries, the
evaluation of treatments for substance use disorders
is in development. In fact, evaluation may well have
had a minor role in influencing what treatment serv-
ices have been developed in a country. Some policy
makers and planners have relied on personal experi-
ence, opinions and testimonials rather than research
data or published studies. This has led to disparities
in the development and management of treatment
services and to the support of interventions of
uncertain effectiveness or efficiency. As we shall
show, evaluation research can help identify which
treatment services are needed as well as assess the
efficiency and effectiveness of existing services. 
Prior to starting any type of evaluation, it is a good
idea to assess the feasibility of the desired research
(see Wholey, 1994). A feasibility assessment should
examine the following:
n results from previous research; 
n the specific questions to be addressed; 
n the size and scope of the study;
n the human resources which will be needed;
n the skills needed by the research team;
n the financial resources needed;
n the timetable for the study
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Communication with 
interested parties
Discussions with interested groups – such as service
providers, clients of treatment programmes, and
treatment funding agencies – can be an invaluable
means of learning about the extent of support for
the study, the direction it should take and practical
issues concerning its implementation. In most situa-
tions those with the greatest interest in evaluation
(the stakeholders) will be treatment programme per-
sonnel, representatives from the community, fund-
ing bodies and government. It may be very helpful
for some stakeholders to serve as members of an
advisory committee for the study. 
Good communication with key stakeholders
throughout the implementation of an evaluation is
vital and they should be involved in an early discus-
sion of findings and implications. It is also important
that a clear understanding of the information
requirements and interests of the funding body is
secured. Discussions with all relevant stakeholders
should be held at the outset and their views and
concerns sought throughout the study. These dis-
cussions will help to formulate the central questions
to be addressed. The aim is to clarify who wants to
know what, by when, with what degree of preci-
sion, and at what cost. Each stakeholder may have
unique experiences and perspectives that can con-
tribute to the overall understanding of the issues
and to the design and implementation of useful
evaluations. 
Different groups may, of course, have different ideas
or emphases on what to evaluate. For example, pol-
icy makers and service purchasers may be most
interested in costs and efficiency, while service
provider staff may be more interested in assessing
the benefits of a new treatment. Naturally, the num-
ber of questions which are worth looking at may
over-stretch the time and resources available. If this
is the case, it is essential that the evaluation team
look at the questions that have the highest priority.
Setting the Stage for Evaluation
Section 1
9Setting objectives
When thinking about the objectives for an evalua-
tion of a treatment programme, it is important to be
clear about how it operates and what it is expected
to achieve. A “logic model” can be of help in repre-
senting these elements as a diagram (see Rush and
Ogborne, 1991). A logic model describes the differ-
ent components of a treatment programme and
what these are designed to achieve (see definitions
box 1). When fully developed, logic models can lead
naturally to the design of management information
systems for the monitoring of services. A logic
model can also be useful when inducting new staff
and for communicating with funding bodies, board
members, clients and others with an interest in the
programme. Two examples of logic models are
shown in boxes 2 and 3.
Resources
Some evaluations can be done quite quickly and do
not require major resources. In fact, relatively simple
and modest studies can be of great value in learning
more about how services operate and how they can
be improved (Rossi and Freeman, 1982). Other
types of evaluation are complex and may need a
substantial investment of funds to be done well. It is
also important to ensure that those to be involved
will have enough time to devote to critical tasks and
that the timetable for the project is realistic. In some
cases resources are allocated and set aside when a
treatment programme is in the planning phase. This
is the ideal situation and policy makers are encour-
aged to support evaluation by earmarking adequate
resources for the evaluation of all new treatment ini-
tiatives. More commonly, evaluations require special
grants from governments and other domestic and
international funding bodies. 
ELEMENTS DESCRIPTION
Programme or system components Activities which are directed to the attainment of specific goals
Implementation objectives What a programme or system seeks to achieve
Short-term outcome objectives Changes which the programme or system seeks to induce in 
its target clients in the immediate or short term.
Long-term outcome objectives Changes which the programme or system seeks to induce in 
its target clients in the longer term.
Components of a treatment programme Box 1
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Logic model for a hypothetical detoxification centre Box 2
Long-term 
Outcome 
Objectives
ASSESSMENT
& INTAKE
DIAGNOSIS &
TREATMENT
PLANNING
WITHDRAWAL
MANAGEMENT
& TREATMENT
REFERRAL
To determine 
eligibility for 
service
n
To assess 
motivation for 
treatment
n
To determine 
individual needs
n
To obtain standard 
somatic, mental 
and psychological 
information
n
To form 
therapeutic 
alliance with client 
and family
n
To provide 
information on 
programme 
To provide 
information 
about treatment 
options
n
To motivate 
clients to seek 
further 
treatment
To monitor 
withdrawal 
symptoms
n
To prescribe 
standard 
medication
n
To conduct 
laboratory and 
other tests
n
To educate family 
and clients
n
To motivate 
clients to 
complete the 
programme
n
To manage 
withdrawal from 
alcohol
To obtain an 
ICD-10 diagnosis
n
To develop a 
treatment plan
n
To sign a 
therapeutic 
contract
Main 
Components
Implementation
Objectives
Short-term
Outcome
Objectives
To increase client’s 
motivation for 
detoxification
n
To identify and refer 
clients needing 
medical care
Complete withdrawal 
from alcohol
n
Stabilisation of mental 
and physical status
To increase client 
awareness of treatment 
options
n
To increase changes that 
clients will accept a 
referral for treatment
Reduced risk of relapse to alcohol abuse
n
Increased social integration
n
Reduced public drunkenness
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Logic model for hypothetical youth services programme Box 3
Long-term 
Outcome 
Objectives
Main 
Components
Implementation
Objectives
Short-term
Outcome
Objectives
ASSESSMENT
& INTAKE
PARENT
PROGRAMME
COUNSELLING EDUCATION STABILISATION
To gather 
basic 
information on 
clients
n
To administer 
standard 
assessment 
instruments
n
To develop a 
treatment plan 
with youth 
and others
To teach 
appropriate 
parenting skills 
and techniques
n
To provide a 
forum for the 
exchange
of mutual 
support for 
parents in 
a group format
n
To educate 
parents about 
consequences 
of PS use on 
the youth and 
the family in a 
group format
To provide 
decision 
focussed 
groups
n
To provide 
individual 
and group 
counselling
n
To implement 
treatment 
plans
To teach risk 
avoidance
n
To provide 
information 
on the 
consequences 
of drug use
To provide 
crisis inter-
ventions to 
adolescents
n
To help clients 
find accom-
modation
n
To teach basic 
life skills
To increase 
client's 
self-esteem
To increase 
self-efficacy in 
avoiding high 
risk situations
n
To increase 
knowledge of 
the impact and 
conse-quences 
of PSU
To stabilise 
clients and 
their situations
n
To improve life 
skills
To reduce psychoactive drug use
To reduce the negative 
consequences of psychoactive 
drug use
To improve the general well being of the client and his/her family system
To improve 
family 
relationships
Getting specialist advice
On occasions, assistance should be sought from
specialists from countries where similar evaluations
have been conducted. A certain amount of technical
expertise is also required. Particularly by the follow-
ing areas:
n Economic analysis;
n Effectiveness and cost-effectiveness;
n Treatment system performance;
n Statistical analysis;
n Study planning and conceptualisation;
Although readily available in some countries, other
countries may have limited expertise in some of
these areas. However, there are usually research
institutions and universities whose staff can assist in
the planning or conducting evaluations and prepar-
ing. Also students from social science, social work
and other relevant courses may be willing to assist
in data collection and analysis to gain work experi-
ence in the evaluation field. It is, however, impor-
tant to recognise that the involvement of university
or college faculty and students may have implica-
tions for the timing of evaluation.
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Ethical issues 
Evaluation can raise ethical concerns. It is critical to
ensure that everyone involved understands the pur-
poses of the evaluation and gives informed consent
to participate. The concerns of potential participants
should be addressed at this stage, particularly issues
relating to confidentiality. Anyone asked to provide
information for an evaluation or to undergo other
procedures for research purposes (e.g. random
assignment to a new form of treatment) should be
asked to sign an informed consent form if they wish
to participate, following adequate information and
resolution of any questions. Confidentiality of infor-
mation should be assured and respected. If there are
circumstances under which confidentiality could be
breached (e.g. records could be subpoenaed by the
courts) then this must be clearly explained in
advance. An appropriate ethics review body should
consider all studies that involve human subjects.
13
Needs assessment
The goal of a needs assessment is to estimate the
current and/or future nature, prevalence and inci-
dence of substance use disorders in a specific popu-
lation. This information is then used to help to guide
the development and operation of treatment and
support services. Ideally, a needs assessment should
be undertaken before a treatment or network of
treatment services is planned and implemented. 
In this section, we describe five main types of evalu-
ation: (a) needs assessment (b) process evaluation
(c) client satisfaction (d) outcome evaluation and (e)
economic evaluation. These may overlap to greater
or lesser degrees. As indicated in Box 4, each type
of evaluation aims to answer certain types of ques-
tions and the decision to undertake a particular type
of evaluation will be determined by the questions of
interest. 
TYPE OF EVALUATION EXAMPLES OF QUESTIONS ADDRESSED
Needs assessment What is the nature and extent of substance use disorders in the community?
How well do current services address the needs of the population at risk?
Process evaluation What is the programme/service/system expected to accomplish?
To what extent is the treatment implemented as planned (programme fidelity)?
Are services of good quality?
What are the views and perceptions of the programme staff on the value 
and quality of the service?
What are the characteristics of the clients of the service?
Which clients do not complete treatment?
Outcome evaluation What proportion of clients complete treatment?
What proportion of clients reduce their drug use after treatment?
Are clients better off than before treatment?
Is our treatment better than no treatment or better than other treatments?
Why does the programme achieve the outcomes that it does? 
Client satisfaction Do clients feel that the treatment met their needs?
What did clients like least or find unhelpful?
Why do some people drop out?
Economic evaluation
Cost studies What is the average cost per client?
Cost effectiveness How do two or more treatments compare in terms of cost per unit of outcome?
Cost utility Given their relative costs, how do two or more treatments compare with respect 
to the quality and quantity of the life of their clients after treatment?
Cost benefit Does the programme yield more benefits than costs valuing everything 
in money terms?
The five major types of evaluation
The Main Types of Evaluation
Section 2
Box 4
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There is no universally agreed definition of 'need' or
how one should assess it. From the perspective of
an individual, “felt need” is what the person wants
(Bradshaw, 1972) and from an epidemiological per-
spective, need can be defined by the ability of that
population to benefit from effective health care
services (Stevens and Raftery, 1994). Sometimes
'need' is used to refer to what people in a commu-
nity believe should be provided or what problems
professionals think should be treated. A needs
assessment can address the gap between existing
services and those needed to adequately treat or
manage known problems in the target population
(Marsden et al., forthcoming). This view of needs
explicitly links the research evidence for particular
interventions into health and social care planning
and delivery. 
Some needs assessments use statistical methods to
estimate the size of the population in need of treat-
ment from survey, treatment utilisation and/or other
indicator data (see DeWit and Rush, 1996). Needs
assessments can also draw on public and profession-
al opinions about what works and what should be
done and they are often commissioned by funding
agencies wanting guidance on how to allocate exist-
ing or new funds. The main types of activities
involved in needs assessments are summarised in
box 5.
Ideally, needs assessment should be an ongoing and
flexible process that is sensitive to changes in the
levels and types of problems within the areas of
concern. Change may be seen in the following
areas: 
n New trends in substance use and consumption
patterns in the target population;
n Movements in the geographical distribution and
concentration of psychoactive substance use; 
n Fluctuations in the demand for services; 
n New barriers to accessing treatment encountered
by special groups;
n The relationship between substance use and other
conditions (notably HIV infection, and blood
borne viral hepatitis); 
n National, regional and local policies in response to
drugs;
n The organisation of health and social care services;
n Changes in the resources available for treatment;
and 
n New evidence for the effectiveness of treatment
interventions.
n Defining the geographic boundaries of the population(s) whose needs are to be considered (local,
regional or national)
n Use of existing population data on the prevalence and incidence of specific problems in the target popu-
lation and in sub-groups
n Use of indicators to provide indirect estimates of the prevalence and incidence of specific problems in
the target population and in sub-groups
n Special population surveys that focus on the issues of concern 
n Focus group discussion with key stakeholders (commissioners, clinicians, treatment providers and service
users) to explore what they want from services
n Reviews of service arrangement in other, similar jurisdictions
n Reviews of the literature on the cost-effectiveness of particular types of interventions 
n Identifying current treatment services and auditing their capacity, use and waiting lists
n Comparing existing arrangements with generally agreed-upon needs or with different perspectives on
existing needs 
n Preparation of recommendations for increasing treatment coverage, purchasing efficiency and service
effectiveness.
Major types of activities in need assessments Box 5
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Process evaluation
Process evaluations look at how a treatment or a
programme operates. Issues such as the efficiency
and quality of treatment services are addressed and
an evaluation made of the extent to which a treat-
ment has been implemented as intended (fidelity
assessment). Process evaluations also try to identify
areas where improvements can be made. Process
evaluations are not directly concerned with changes
in clients that may result from the treatments
received. They focus on how treatment services or
systems operate and the ways in which resources
are used to produce outputs (e.g. number of clients
assessed; numbers treated). Specific questions for a
process evaluation can include the following: 
n The extent to which a service or system is concep-
tually or theoretically sound;
n Whether the clients served are those intended;
n Whether clients experience difficulty in accessing
the programme; 
n The extent to which the programme staff are ade-
quately trained and the extent to which they are
satisfied with their work. 
Process evaluations may also consider internal and
external coordination, organisational and service
management issues and case management and
record keeping (see box 6 and 7). The steps that
may be taken when conducting a process evaluation
are shown in box 8:
Questions and issues addressed in process evaluation
n Focus on single programme, service or agency
n Number and characteristics of clients served (see box 7)
n Nature and extent of treatment(s) provided
n Ease of access to target groups
n Costs of service
n Programme logic
n Staff qualifications
n Quality of records
n Discharge planning and aftercare arrangements
n Case management 
n Internal and external co-ordination
n Compliance with established standards
n Characteristics of environment that impact programme delivery
n Focus on a network or system of services or agencies
n Characteristics of clients served by different agencies (see box 7)
n Referral and cross-referral patterns
n Case management across services
n Intra-agency co-ordination in planning for direct client service 
n Characteristics of broader environment that impact the function on the system
Box 6
Process evaluations are closely related to pro-
gramme audits and continuous quality improvement
(CQI) initiatives. CQI focuses on customer satisfac-
tion, accurate measurement of activities, ongoing
improvement of services and operational processes,
and meaningful involvement of people at all levels
in the organizational process. Other ingredients,
including programme logic models, integrated care
pathways, client satisfaction surveys and routine
outcome monitoring, can all be part of CQI. The
results of process evaluations may have important
implications for individual staff and managers. 
Space limitations preclude a discussion of routine
treatment utilisation and audit systems. These pro-
vide valuable information about the operation of a
treatment system. Setting up monitoring systems
that routinely provide information on the operation
of a treatment service or system can also reduce the
costs of process evaluations.
Client satisfaction studies
The assessment of client satisfaction can add an
important “consumer” perspective to evaluations of
treatment services and systems (Lebour, 1983).
Without such a perspective, problems such as high
drop out or low success rates might be related only
to client factors when, in reality, these problems
may reflect shortcomings in the services provided or
in the treatment system. However, it is important to
recognise that evidence of client satisfaction is not,
in itself, sufficient to establish the effectiveness of a
treatment. Clients with no base for comparison may
be satisfied with services that more objective meas-
ures show are of poor quality. In the short-term,
clients may also indicate high satisfaction with serv-
ices that are well run yet quite ineffective. Likewise,
clients may express dissatisfaction with services that
are successful nonetheless in reducing their sub-
stance use. 
Client satisfaction surveys can be used for routine or
periodic “check-ups” on the quality of services from
the clients' perspectives. They can also be used to
assess client reactions to changes in service delivery.
For example, a service may have planned changes
to increase its efficiency but be concerned that these
could lead to decreased client satisfaction. Client
satisfaction surveys are most useful when they are
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designed to meet specific objectives and when they
use appropriate methods and measures. Sampling
procedures, timing, cultural acceptability and sensi-
tivity of the questions to various levels of satisfac-
tion must all be considered carefully.
The most common method for assessing client satis-
faction is to use a confidential self-administered
questionnaire. This can be given to clients at dis-
charge or follow-up. In some cases, confidential per-
sonal or telephone interviews, or focus groups may
be more appropriate. If interviews or focus groups
are used, it is preferable to have them conducted by
someone who is not directly connected with the
Client characteristics considered 
in process and/or 
outcome studies
n Number of clients served
n Age, gender (intake)
n Source of referral (intake)
n Treatment history (intake)
n Motivation for treatment and readiness for
change (intake)
n Post-intake treatment from index treatment
and elsewhere
n Marital/partnership status
n Education
n Work situation/income levels
n Accommodation status and stability
n Involvement with justice system
n Health and social service use
n Alcohol and drug use levels and patterns
n Level of alcohol/drug dependence
n Adverse consequences of alcohol/drug use
n Mental health problems
n Physical health problems
n Self-esteem
n Coping skills
n Social relationships
Box 7
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service. This may be an independent evaluator, vol-
unteer or former client trained to take on this role.
In all cases clients should be assured that their
responses would not in any way affect their present
or future treatment. 
It is important to take cultural differences into
account regarding expectations of feedback on pub-
lic and private services. In jurisdictions where con-
sumerism is firmly established, frank verbal or writ-
ten feedback may be freely given. However, direct
negative feedback in some cultures may be consid-
ered impolite and complaints may only be shared
with intimate acquaintances. Direct and challenging
questions may also be culturally inappropriate.
Experiences with (and attitudes toward) the use of
questionnaires, interviews, focus groups and other
methods of enquiry also differ between cultures.
Methods for soliciting client feedback must take into
account the prevailing cultural norms and seek to
ensure the use of appropriate methods that assess
client beliefs and opinions. In addition to using con-
fidential survey methods there is increasing interest
in establishing channels through which service users
can have an active input into service delivery. Some
of the specific issues that could be addressed in
client satisfaction studies are indicated in box 9.
Outcome evaluations
Outcome evaluations look at whether clients of a
treatment service or system have changed over time
and how much of this can be attributed to the care
received. Although such evaluations sometimes
involve single clients, usually one or more groups of
clients that have received a certain treatment within
the system are involved. In the past, most outcome
studies of people treated with substance use prob-
lems used post-treatment abstinence from sub-
stances as a primary indicator of treatment success.
However, modern studies focus more on patterns
and levels of post-treatment substance use and also
consider post-treatment functioning in other life
areas. Three other problem domains are usually
assessed: health risk behaviours, health problems
and various aspects of personal/social functioning,
including employment, family and other personal
relationship problems and criminal behaviour. Box 7
summarises some of the specific issues commonly
considered. Further details and information on spe-
cific measurements and procedures are provided in
the WHO/UNDCP/EMCDDA workbook on out-
come evaluation. We recommend that expert advice
is sought in the selection of measures for particular
studies, especially in cases where new measures are
to be developed. Particularly attention should be
paid to issues of reliability and validity (see
Section 3: Special issues).
Major activities in process evaluations
n Review of original planning documents concerning the need for the service/system, the objectives, the
specific treatment methods used and the resources that were thought be to required
n Focus groups or interviews with programme participants or others such as community planners, man-
agers, staff, community agency representatives and families
n Development and critique of programme logic models 
n Chart audits
n Analysis of information from built-in management information systems
n Observation of the programme(s) in action, for example, to rate the extent and quality of implementa-
tion and integration with other programmes;
n Surveys of the population for whom the programme or treatment system was intended and of actual
programme participants.
Box 8
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achieved and to identify which clients change most
or least. They can also show how outcomes vary
with the amount or type of treatment received.
However, observational designs cannot definitively
conclude that any observed changes were caused by
the treatment(s) of interest. This is because they do
not control for many of the other factors that might
explain the changes observed (e.g. non-treatment
factors, maturation, cyclical changes). 
In some circumstances it may be feasible to obtain
one or more comparison groups of cases that are
similar to the clients of a target treatment but who
have not been treated or have been treated by
some alternative means. If the groups are initially
very similar, then it can be assumed that any differ-
ences over time are at least partly due to differences
in treatment. Suitable comparison groups might be
cases treated in a different programme or cases
included in studies reported in the literature.
However, it is important to ensure that the treat-
ment and comparison groups are as similar as possi-
ble and not specifically selected to give them an
advantage in any one case (e.g. screened for moti-
vation or social stability).
Experimental, controlled designs
Experimental designs involve the allocation of clients
to one or more treatments or to a no-treatment or
waiting list (delayed treatment condition). In ran-
domised controlled trials, a simple randomisation or
group balancing procedure is used to allocate clients
to the experimental or comparison treatment (usual-
ly the “standard” form of care which is usually
delivered) condition. In substance use treatment,
these designs are often conducted in the context of
the day-to-day operation of a treatment programme
and are known as randomised clinical trials or ran-
domised field experiments (see Dennis 1994).
When properly conducted, experimental designs can
produce the most convincing evidence that meas-
ured outcomes were due to the treatment studied.
However the validity of experimental designs can be
compromised unless care is taken to adhere to the
study procedure and the treatments are implement-
ed as planned. A common problem is that it may be
difficult to ensure that those in different treatment
conditions actually receive the same amount of
When conducting an outcome evaluation, it is
important to develop a theory or at least a frame-
work for accounting for why a treatment process
achieves a measured outcome (Chen, 1990). Process
evaluations are the logical partner to outcome eval-
uation and good quality outcome evaluation should
always have a process component. There are several
different designs that can be used in outcome evalu-
ations.
Naturalistic, observation studies
In naturalistic or observational studies clients are
assessed on a set of measures at several points in
time – usually before, during and after they com-
plete a treatment programme of interest. These
studies are useful for the study of treatment systems
where clients engage in multiple treatments of vary-
ing intensities and duration. There have been several
major multi-site naturalistic post studies conducted
including the Drug Abuse Treatment Outcome
Study (DATOS) in the United States and the
National Treatment Outcome Study (NTORS) in the
United Kingdom (http://www.datos.org;
http://www.ntors.org.uk). These sorts of study can
be used to show if the desired client outcomes are
Questions and issues addressed 
in client satisfaction studies
n Physical setting of treatment
n Helpfulness of staff
n Costs of treatment
n Accessibility of services
n Family involvement
n Waiting times
n Information
n Amount of service
n Effectiveness
n Case management and co-ordination
n Confidentiality
Box 9
attention when two treatment methods are being
compared. For example, clients and therapists may
not be equally enthusiastic about the treatments
being compared. If not, the outcomes for some
treatments may be deflated because no one
believed they would work or made much effort to
deliver them as planned. As with comparison group
studies there are technical and logistical problems
with the design and conduct of experimental evalu-
ations. Consultation with an experienced evaluator
is strongly recommended if an experimental design
is being considered.
Economic evaluations
Economic evaluations assess the resources required
to provide treatment and the resulting benefits. A
central question posed by many economic evalua-
tions is whether the treatment or treatment system
studied is an efficient use of resources (see
Drummond et al., 1987). Treatment funding agen-
cies are increasingly demanding that treatment serv-
ices and systems be evaluated from an economic
perspective. However, the economic evaluation of
treatment is still an emerging discipline and there
are only a few published studies that can be charac-
terised as full economic evaluations. 
It is important to be aware that economic evalua-
tions are undertaken from a particular perspective
and that the results can vary with the perspective
taken. Generally, the perspective taken is that of
society as a whole or that of the agency providing
funds for treatment (usually the government).
However, economic evaluations can also be con-
ducted from the perspectives of clients or family
members. Overall, economic evaluations can be
complex and time consuming; since there are many
technical and logistical issues to consider we recom-
mend that consultation with an expert is well worth-
while. There are three types of economic evaluation:
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Cost analysis
A cost analysis determines the overall cost of the
resources used to provide a treatment activity, serv-
ice or system. These may include both direct costs
(such as clinical staff salaries) as well as overheads
such as building and maintenance costs, administra-
tive salaries, equipment and supplies. The amount of
direct resources used for specific activities can be
measured and the indirect resources apportioned.
The results are then used to compute various indica-
tors of economic performance (e.g. costs of residen-
tial treatment per client per week or episode; cost
per counselling visit). This type of economic evalua-
tion is, however, quite limited and it is important to
recognise that the relative costs of treatment pro-
grammes may not reflect their relative effectiveness.
Sometimes lower cost programmes may be as effec-
tive as those costing a lot more (Holder et al.,
1991). However, for people who also have multiple
social and mental health problems in addition to
their substance-related difficulties, comprehensive,
and usually higher cost interventions are likely to be
more effective than more basic and lower cost inter-
ventions (McLellan et al. 1998).
Cost-effectiveness analysis
Cost-effectiveness analysis (CEA) compares the costs
and outcomes of two or more different treatments
with similar objectives. Examples of outcomes used
for a CEA include: “number of cases that achieve a
certain outcome or degree of success” or “duration
of abstinence of rehabilitation following discharge”
or perhaps a “reduction in substance-related prob-
lems”. Multiple outcomes are sometimes considered
and the results may vary with different outcomes.
For example, one treatment may be more cost effec-
tive than another at reducing drug use but less cost
effective at increasing employment. The first stage in
CEA is usually to estimate the costs per patient out-
come achieved (via a decision analysis). The second
stage involves comparison of the cost-effectiveness
ratios for each of the treatments studied.
Cost-utility and cost benefit analysis
Cost utility analysis (CUA) uses ratings of the quality
of life and life expectancy and survival of clients
who have been treated as primary outcome meas-
ures. Often these ratings are used to compute a
measure of 'quality adjusted life years' (QALYs) that
are used to indicate a degree of discrepancy
between a client's actual outcome status and an
ideal status from a client's own perspective. CUA is
increasingly viewed as more appropriate for health
case evaluation than cost-effectiveness analysis
because the latter does not take intangible benefits
or the quality of outcomes into consideration.
In cost benefit analysis (CBA) the costs of delivering
treatment and the outcomes from treatment are
both measured in monetary units. For example, the
costs of health or social services used or the
increased tax revenues paid by employed drug
users. These types of studies are uncommon and
there is some criticism of the appropriateness of
measuring outcomes solely in monetary terms. In
addition to other technical matters, these studies
require attention to the issues of discounting. This
occurs because the economic benefits of a pro-
gramme can occur long after the programme costs
are used up. The 'future values’ of these benefits
therefore need to be assessed in terms of present
day realities and the lost opportunities to use
resources in other ways. Comprehensive economic
evaluations require two or more suitable alternatives
to be evaluated. The most desirable design to
demonstrate robust effects is the randomised con-
trolled trial. However, the choice of design for an
economic evaluation should be guided by the main
questions being addressed.
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In this section, we discuss a number of important
issues that are of a more technical nature. They
apply to all types of evaluations – but there several
specific matters that are of particular concern in out-
come studies. Guidelines on data analysis are
beyond the scope of this document and space limi-
tations also prohibit discussion of the distinctions
between qualitative and quantitative evaluation
methods. Basic information on data collection and
analysis and on other technical issues can be found
in the WHO/UNDCP/EMCDDA workbooks. The
issues are also covered in numerous basic and
advanced textbooks on evaluation.
Reliability, validity and sensitivity of
measures 
Measures are observations or ratings of behaviour,
attitudes, beliefs and the like. The principal require-
ments of a measuring device (such as a question-
naire) are that it should measure what it is supposed
to measure (validity) and do so consistently (reliabili-
ty). There are several ways to assess validity and
reliability that allow different inferences to be made.
The reliability of measures used in evaluation
research can be assessed by examining consistency
across time (test-retest-reliability) and consistency
across observers (inter-rater reliability). Internal con-
sistency is a useful measure of reliability for multi-
item scales. This indicates the extent to which all
items measure a single construct.
Several kinds of validity can be used for the meas-
ures used in programme evaluation. Face validity
refers to whether the contents of specific questions
or measures reflect what the indicator is supposed
to measure. Assessments of validity of a measure
are usually undertaken in three ways:
n coverage of all the salient features of the intended
construct (content validity); 
n by ensuring that the instrument does not include
phenomena germane to other constructs (con-
struct validity); and 
n there is a strong positive correlation between
scores on the instrument and other related instru-
ments designed to measure the same construct
(concurrent validity). 
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Special Issues
Ideally, a chosen measure must also be free from
response bias and be non-reactive (insensitive) to
extraneous factors (including physical setting, client
expectation, staff behaviour and accountability pres-
sures). Measures must also be sensitive to changes
in the phenomena studied. A measure may be valid
yet not sufficiently sensitive to measure subtle but
important changes. Generally, the sensitivity of a
measure increases with the range of possible scores
it has. Thus a dichotomous response item – (e.g. yes
or no) – will probably be less sensitive than a scale
made up of several items.
Reliability of self-report data
Self-report is the most commonly used data source
in evaluation studies. There is sometimes concern
about the reliably and validity of such reports. Often
these concerns are overstated. The validity of self-
report information cannot be considered independ-
ently from the method used to obtain the report
and will therefore vary across measurement con-
texts. The extent to which self-report is reliable,
depends on a set of dynamic factors (see Babor,
Brown and Del Boca, 1990). These include the fol-
lowing: 
n the characteristics of the client (e.g. physical and
psychological state; motivation and fatigue); 
n contextual and task variables (e.g. context and
setting for the data collection; confidentiality
assurances; nature of the questions and answer
format); and 
n cognitive factors (e.g. comprehension and memo-
ry and retrieval processes) 
In addition to client self-report there may be an
opportunity to gather other collateral information
including biological data. Biological measures such
as urine, blood or even hair can be collected and
analysed for drugs. There are advantages and disad-
vantages with each type of sample and expert
advice is therefore recommended in the design, use
and interpretation of biological data of this sort
(Wolff et al., 1999).
Time periods for measures
An important decision concerns the time period over
which outcomes will be assessed. For example,
although a follow-up period may be six months in
Section 3
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duration, a decision needs to be reached about the
time period over which clients will be asked to recall
the key outcome measures. The same time period
should be chosen for both baseline assessment and
the follow-up interview. For most indicators, the rec-
ommended recall periods are 30 days and 90 days.
Assessing non-treatment factors that
may affect outcome
When people with substance use disorders engage
with treatment they are almost always exposed to
other influences in their personal and social lives.
These influences can exert either a positive or nega-
tive influence on the client’s ability and willingness to
change behaviour (see for example, Moos, Cronkite
and Finney, 1994). For example, a client may have
contact with friends who are problematic substance
users or experience a sudden social problem (such
homelessness) and this may increase the risk of
relapse. These influences are important and evalua-
tors should try to measure the nature and extent of
these factors when assessing treatment outcome.
There are also several non-treatment factors that
may operate when assessing the impact of a treat-
ment programme on a cohort of clients. Firstly,
some clients may not really fully engage with the
programme but simply 'mature-out' of drug use.
This is particularly likely to be the case with younger
substance users. Secondly, some clients who
approach treatment services may have periods of
relative stability or instability that occur independ-
ently of any treatment received. Thirdly, there is a
rather confusing statistical artefact called 'regression
to the mean' which can influence change scores for
groups on measures that are not completely corre-
lated and differ from a theoretical “true” score (a
statistician should be consulted to review this issue).
Fourthly, the data collection and evaluation process
itself may influence clients. They may, for example,
be motivated to respond in a positive manner to the
follow-up interviewer. A follow-up interviewer who
is in contact with clients on several occasions may
also motivate them to change by asking questions
and showing an interest in their situations. Various
research designs can be used to control for the
influence of non-treatment factors on client out-
come. No one method is universally effective and no
single study is ever definitive. It is the convergence
of research evidence from different study designs
undertaken by different investigators in different
countries that enables conclusions to be drawn
about the role of treatment and non-treatment fac-
tors in patient outcomes. 
Subject recruitment and follow-up
For outcome studies, an unbiased sample of subjects
should be recruited at entry to a treatment pro-
gramme. Baseline evaluation information (pre-treat-
ment assessment) should be collected as early as pos-
sible in the intake/assessment process. At entry to
treatment some clients may be unable to participate
in a study due to physical and psychological health
complications. Recall periods should be timed from
entry into treatment in these situations (and the time
from intake to baseline data collection noted).
An “intent-to-treat”follow-up strategy is also rec-
ommended for all outcome evaluations. This means
that all clients recruited are sought for follow-up
and not only those who completed treatment. There
is a general consensus that at least 70% of subjects
recruited to an outcome study should be followed-
up for the results to be reliable. The timing of fol-
low-up points is also important and published stud-
ies report on information obtained at many different
points in time. Some evaluations report on client
changes at the time of discharge or after a particular
period of contact. Other evaluations have followed
samples of clients for several years. Most common
are reports of outcomes assessed at three, six, or 12
months after treatment has ended. The timing of
follow-up and the intervals considered will have a
significant impact on the results and conclusions
drawn from a study. Short-term follow-up studies
are likely to show better results than longer term
ones. This is because between 60% and 80% of
'relapses' to substance use occurs in the first three
to four months following discharge. Results will
depend on the type of outcome being assessed. For
example, changes in drinking and drug use may not
be stable, but long-term overall improvements in
family functioning may occur. Overall, the selection
of follow-up periods and intervals must be consis-
tent with the objectives of the evaluation if it is to
produce useful results. 
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Sampling and sample size
A sampling strategy refers to the methods used to
select the representative “units” (such as treatment
agencies or treatment participants) to be included in
a study. A sampling procedure that assures that
each element in the population has an equal chance
of being selected is referred to as “simple random
sampling”. Sometimes a systematic random sam-
pling method can be used where a starting point is
chosen (e.g. sampling every 20th school in a popu-
lation or every 20th class member). An alternative
to simple random sampling is stratified random sam-
pling. This method is normally used where: 
n It is not possible to generate a list of all the mem-
bers of a population; 
n where the members of a population are too geo-
graphically dispersed to be contacted; and 
n where the population contains important sub-
groups that are either of variable sizes and/or
geographically dispersed. 
In contrast to simple random sampling and stratified
sampling, (where single subjects are selected from
the population), in “cluster sampling” the subjects
are selected in groups or clusters. Cluster sampling is
commonly used when the population is very geo-
graphically dispersed and may already form natural
groups.
When considering the size of a sample that is
required, this is to some extent determined by the
nature of the study, its objectives and the measures
to be used. In outcome studies that aim at compar-
ing outcomes for two or more groups of clients, the
sample size depends on the magnitude of the differ-
ence on a specified outcome measure that is
required to detect change between the groups. A
statistician can assist in calculating the required sam-
ple size based on the following information:
n the degree of confidence one wants in the results
obtained; 
n the relative sizes of groups to be compared; 
n the expected frequency of the behaviour in one
group; and
n the magnitude of the difference that is to be
detected between the groups to be compared
When determining the number of people to be fol-
lowed-up in an outcome evaluation, allowance
should be made for clients who cannot be contacted
and for whom outcome information will be missing.
It is reasonable to expect that up to 30% of cases
chosen for follow-up cannot be traced. The sample
selected for follow-up should therefore be increased
by 30%. 
Sample size is also important in needs assessment
surveys. In general, the required sample size in such
cases is smaller than commonly believed. However,
it depends on the number of subgroups that may be
of interest and the expected accuracy of results.
Consultation with a statistician is recommended for
the design and analysis of studies involving survey
samples. 
Statistical testing and confidence
intervals
Almost all outcome evaluations involve an element
of statistical testing. In a randomised controlled trial,
for example, researchers will ask about the “statisti-
cal significance” of differences in response measures
between the control and experimental group(s) at
intake and follow-up and between these two points.
The conventional way of tackling this question is to
use statistical hypothesis testing. This usually starts
with the assumption that there is no difference
between groups (the so-called null hypothesis). A
statistical test is then used to see if any observed
difference can be considered genuine (at the popu-
lation level) or due to chance. It is quite common
for researchers to present the values of a statistical
test and to indicate the probability that the
observed difference is due to chance. However, this
only indirectly tells the reader how much confidence
to have in the results. It is therefore recommended
that evaluation studies also report the magnitude of
differences over time and between groups in
absolute value where the measure is meaningful
(e.g. a mortality rate) and in standard deviation
units when the outcome is measured in an essential-
ly arbitrary way (e.g. a score on an attitude scale).
The upper and lower limits of a confidence interval
around this estimate should also be provided (the
95% bound is commonly used). 
In this section, we consider the reporting of the
results of an evaluation and how to apply the
results. Each of the types of evaluation discussed in
this document will lead to a report with some
unique features. As an example, only reports for an
outcome evaluation will be considered here. Box 10
shows one possible structure for an outcome evalu-
ation report. This has been informed by the profes-
sional consensus statement published in the Journal
of the American Medical Association on key infor-
mation to report from clinical trials (see Begg, et al.,
1996). The box presents a more generic overview of
the sorts of material to include in a formal report.
An executive summary of the evaluation should be
prepared and this is a valuable means of describing
the key findings and significance of a study to a
wide audience.
Increasing the impact of evaluation
It is unfortunately the case that evaluations of treat-
ment for substance abuse do not always have an
impact on decisions about what treatment pro-
grammes will be supported and how treatment will
be delivered (Miller, 1987; Ogborne, 1988). There
are many reasons for this including the vested inter-
ests of some treatment providers, the poor quality
of some evaluations and, in some instances, the lack
of clear-cut results. However, the impact of evalua-
tion may also be limited by poor communication
between evaluators and decision-makers. 
The importance of involving key decision makers in
the earliest discussions of evaluation will increase
the chances that evaluations will generate timely
and useful information. Good communication goes
well beyond simply providing funding bodies copies
of evaluation reports. These reports are often
lengthy and sometimes quite technical and may fail
to hold readers’ attention. Also reports in them-
selves may not be sufficient to convince decision
makers that particular programmes should be sup-
ported. This is especially so when evaluations sug-
gest that new programmes would have to be fund-
ed at the expense of existing programmes or that
existing programs need to be radically altered. In
these cases there is likely to be opposition to change
from those with a vested interest in the status quo.
Resistance to change can also occur when there is a
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lack of skills and resources in existing delivery sys-
tems or lack of understanding of the need for
change and a lack of appreciation of the benefits of
change. In some cases prevailing belief and value
systems can impede the adoption of new treatments
and in others cases resistance to change reflects
fears for loss of jobs or status among service
providers.
Several strategies have been proposed for increasing
the impact of evaluation and there is also a large lit-
erature on the diffusion of innovation that has some
important lessons for those seeking to promote
evaluation and the adoption of treatments for sub-
stance abuse (Davis, 1978; Eveland, 1986; Backer,
1991). It is recommended that, where possible, pri-
ority should be given to ways that clearly demon-
strate the advantages of evidence-based treatments.
This might include the implementation of special
demonstration projects to be visited by those inter-
ested in using the same methods. The demonstra-
tion programmes can also provide on-site training
opportunities. As well it would be useful to develop
clear guidelines or “how to” manuals for using the
new methods.
Change agents – people who aim to bridge the gap
between knowledge and practice by actively pro-
moting evidence – based practices – have proved to
be helpful in many situations. These should be peo-
ple who have, or are able to earn the respect of
those they seek to influence and who have a good
understanding of new methods. They need strong
interpersonal skills and the ability to find creative
ways to promote change in different contexts.
Reporting Results
Section 4
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HEADING SUBHEADING DESCRIPTION 
Title Description of study and the research team and source of any 
funding support
Abstract Structured format (e.g. aims and objectives; study design; 
treatment(s) studied and their settings; participants; measurements; 
methods and procedures; findings; conclusions)
Introduction Background to the study and summary of relevant previous research
State prospectively defined hypothesis, clinical objectives, 
and planned subgroup or covariate analysis
Methods Protocol Subject population studied
Participant inclusion/exclusion criteria
Interventions studied (modality; intensity and duration)
Primary and secondary outcome measure(s) 
Describe how sample size was calculated (power calculation)
Plan for statistical analysis (main and subsidiary analyses)
Procedure Subject recruitment methods
Unit of randomisation (e.g. individual, cluster, geographic) – if used
Randomisation methods
Number and timing of follow-up points
Subject tracking procedures and interview methods 
(e.g. face-to-face; telephone; self-completion) 
Results Descriptive Study profile (figure) summarising number of participants 
through the study 
Numbers of subjects in treatment over time and numbers interviewed 
and lost to the study at follow-up 
Baseline subject characteristics
Inferential Effect of programme on primary and secondary 
outcome measures
Discussion/ Summary of main findings
commentary Extent of bias and/or design weaknesses and study limitations
Implications of the findings
Recommendations
Structure and content of a formal report 
from an outcome evaluation Box 10
Summary and Conclusions
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There is still much to be learned about the most
effective, efficient and humane ways to help people
with substance use disorders and to reduce the
associated harms to users themselves and to others.
There are still many treatments that have not been
rigorously evaluated and some treatments, found
effective in some context or cultures, have not also
been tested in others. The emergence of new drugs,
new types of drug users and new patterns of use
may also require the development of new treat-
ments that need to be evaluated. Evaluation should
therefore be a feature of treatment systems and
treatment policy. Evaluation will help to (a) identify
treatment needs (b) plan needs-based interventions,
(c) show if these interventions are consistent with
needs and plans and (d) show if theses interventions
are effective and efficient. 
These guidelines summarise the main features of
evaluation and we hope that they will motivate the
reader to support and champion the evaluation of
substance abuse treatment within their countries
and communities. It is also hoped that readers will
be motivated to learn more about evaluation and be
interested in consulting the WHO/UNDCP/EMCD-
DA workbooks.
The guidelines have not attempted to conceal the
fact that some types of evaluation are quite com-
plex and require special skills. This would be a dis-
service to the cause of evaluation and to the many
people who have worked hard to develop the eval-
uation methodologies that are helping to improve
treatment in some contexts. We have, however, also
attempted to show that evaluation does not have to
be daunting. All readers are strongly encouraged to
consider supporting or undertaking basic evaluations
even if more complex alternatives are not at present
feasible. These initial efforts can later be extended
as more skills are acquired and more resources
become available. Evaluations and related activities
that do not require highly special skills or extensive
resources are:
n Need assessments that use existing quantitative
data and/or key informant interviews;
n Use of logic models to plan new services and to
clarify the assumptions and objectives of existing
programmes or systems;
n Development and implementation of basic, rou-
tine or periodic monitoring systems to show (1)
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1994). 
Adams E.H, Kopstein A.N The non-medical use of
*prescription* drugs in the United States. In: 
Cooper J.R., Czechowicz D.J, Molinari S.P., Petersen
R.C. (Eds.) Impact of Prescription Drug Diversion
Control Systems on Medical Practice and Patient
Care. NIDA Research Monograph 131. Rockville
MD: National Institute on Drug Abuse, 1993.
Babor, T.F., Brown, J., & Del Boca, F.K. Validity of
self-reports in applied research on addictive behav-
iours: fact or fiction? Behavioral Assessment,
1990,12: 5-31.
Backer, T.E. Drug abuse technology transfer. NIDA
monograph serious # 1555; Rockville, MD; National
Institute on Drug Abuse, 1991.
Begg, C., Mildred, C., Eastwood, S., Horton, R.,
Moher, D., Olkin, I., Pitkin, R., Rennie, D., Schulz,
K.F., Simel, D. & Stroup, D.F. Improving the quality
of reporting of randomised controlled trials. Journal
of the American Medical Association, 1996,
276:637-639.
Bradshaw, J.S. A taxonomy of social need. In:
McLachlan, G. (Ed.) Problems and Progress in
Medical Care: essays on current research. 7th series.
Oxford: Oxford University Press, 1972. 
Centre for Substance Abuse Treatment The Costs
and Benefits of Substance Abuse Treatment.
Available online at [http://neds.calib.com/prod-
ucts/pdfs/costben.pdf], 1999.
Chen, H.-T. Theory-driven evaluations. Newbury
Park: Sage, 1990.
Davis, H.A. Management of change and innovation
in mental health services. Hospital and Community
Psychiatry, 1978, 29: 649-658.
Dennis, M.L. Ethical and practical randomised field
experiments. In: Wholey, J.S., Hatry, H.P.&
Newcomer, K.E. (Eds.) Handbook of Practical
Program Evaluation. San Francisco: Jossey Bass,
1994.
DeWit, D.J., & Rush, B.R. Assessing the need for
substance abuse services: A critical review of needs
assessment models. Evaluation and Program
Planning, 1996, 19: 41-64.
27
Drummond, M.F., Stoddart, G.L. & Torrance, G.W.
Methods for the economic evaluation of health care
programmes. Oxford: Oxford University Press,
1987.
Eveland, J.D. Diffusion, technology transfer and
innovation. Thinking and talking about change.
Knowledge: Creation, Diffusion and Utilization,
1986, 8: 303-322.
Graham, K, Woo, G.A. Smythe, C. and others The
Evaluation Casebook: Using Evaluation to Enhance
Program Quality in Addictions. Toronto: Addiction
Research Foundation. (Now part of the Centre for
Addiction and Mental Health), 1994.
Holder, H., Longabaugh, Miller, Rubonis. The cost
effectiveness of treatment for alcoholism first
approximation. Journal of Studies on Alcohol, 1991,
52: 517-525.
Holder, H.D. & Blose, J.O. The reduction of health
care costs associated with alcoholism treatment: A
14 year longitudinal study. Journal of Studies on
Alcohol, 1992, 53: 293-302.
Landry, M. Overview of Addiction Treatment
Effectiveness, Office of Applied Studies.
116.Rockville, MD: SAMHSA, 1995.
Lebour, D.L. Similarities and differences between
mental health and health care evaluations studies
assessing consumer satisfaction. Evaluation and
Programme Planning, 1983, 2:197-245.
Marsden, J., Strang, J. with Lavoie, D., Abdulrahim,
D., Hickman, M & Scott, S. Epidemiologically-based
needs assessment: Drug misuse. In: Stevens, A. &
Raftery, J. (Eds.) Health Care Needs Assessment.
Oxford: Radcliffe, forthcoming.
McLellan, A.T., Hagan, T.A., Levine, M., Gould, F.,
Meyers, K., Bencivengo, M., and Durell, J.
Supplemental social services improve outcomes in
public addiction treatment. Addiction, 1998,93:
1489-1499.
Miller, W.E. and Hester, R.K. The effectiveness of
treatment techniques: what works and what does-
n't, in Treating addictive behaviours: processes of
change, W.E. Miller and N. Heather, Editors, Plenum
Press: New York, 1986.
References
28
Miller, W.R., Behavioral alcohol treatment research
advances: barriers to utilization. Advances in
Behavior Research and Therapy, 1987, 9: 145-164.
Moos, R.H., Finney, J.W. & Cronkite, R.C.
Alcoholism treatment. Context, Process and
Outcome. New Yor: Oxford University, 1990. 
National Institute on Drug Abuse, Principles of Drug
Addiction Treatment: A research-based guide,
National Institutes of Health: Washington D.C,
1999.
Ogborne, A.C. Bridging the gap between the two
cultures of alcoholism research and treatment.
British Journal of Addiction, 1988, 83: 729-733.
Roberts, G. and Ogborne,A.C., Best Practices:
Substance Abuse Treatment and Rehabilitation,
Office of Alcohol, Drugs and Dependency Issues,
Health Canada: Ottawa, 1999.
Rossi, P.H., & Freeman, H.E. Evaluation: A systemat-
ic approach (2nd Ed.). Beverly Hills, California: Sage
Publications, 1982.
Rush, B.R., & Ogborne, A.C. Program logic models:
Expanding their role and structure for planning and
evaluation. Canadian Journal of Program
Evaluation, 1991,6(2): 95-106.
Rydell, C.P. and S.S. Everingham, Controlling
Cocaine: Supply versus Demand Programs, Rand:
Santa Monica, CA, 1994.
Single, E., Robson, L., Xie, X., Rehm, J. The costs of
substance abuse in Canada. Ottawa. The Canadian
Centre on Substance Abuse, 1996.
Stevens, A. & Raftery, J. Health Care Needs
Assessment. The Epdemiologically based needs
assessment reviews. Oxford: Radcliffe Medical
Press, 1994.
Tims, F. Drug Abuse Treatment Effectiveness and
Cost-Effectiveness, Rockville, Maryland: National
Institute on Drug Abuse, 1995.
United Nations International Drug Control
Programme World Drug Report. Oxford University
Press, New York, 1997.
Wholey, J.S. Assessing the feasibility and likely use-
fulness of evaluation. In: J.S. Wholey, J.S., Hatry,
H.P. & Newcomer, K.E.(Eds.) Handbook of Practical
Program Evaluation. San Francisco: Jossey Bass,
1994. 
Wolff, K., Farrell, M., Marsden, J., Monteiro, M.G.,
Ali, R, Welch, S. & Strang, J. A Review of Biological
Indicators of illicit drug use: practical considerations
and clinical usefulness. Addiction, 1999, 94: 1279-
1298.
World Health Organization, United Nations Drug
Control Program and European Monitoring Centre
on Drugs and Drug Addiction Evaluation of
Psychoactive Substance Use Disorder Treatment.
Facilitators Manual and Workbooks 1-8. WHO
Geneva, 2000.
WHO Expert Committee on Drug Dependence,
30th Report, World Health Organization: Geneva,
1996.

